|
|
GEO help: Mouse over screen elements for information. |
|
Status |
Public on May 01, 2024 |
Title |
Preclinical study on safety and efficacy of GMP human umbilical cord mesenchymal stem cells in knee osteoarthritis |
Organism |
Macaca fascicularis |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Clinical trials of MSCs in the treatment of OA have been carried out and good results have been obtained. However, these data on the dose of transplanted cells, the number of transplants, the therapeutic effect especially cartilage regeneration and safety are incomplete. Therefore, we constructed a cynomolgus macaque model consistent with the pathogenesis of OA. We have also established clinical-grade human umbilical cord-derived mesenchymal stem cell line. We selected two cell doses (2.5*10e7 cells per knee and 5*10e6 cells per knee, respectively) to assess differences in treatment effects and to assess the systemic safety of MSC therapy. High-dose hUC-MSCs can regenerate cartilage, increase joint space, and improve bone condition by ultrasound and MRI scans. But low-dose hUC-MSCs simply prevented further deterioration of the joint
|
|
|
Overall design |
First, we constructed a cynomolgus macaque model consistent with the pathogenesis of OA. We have also established clinical-grade human umbilical cord-derived mesenchymal stem cell line. Then we selected two cell doses (2.5*10e7 cells per knee and 5*10e6 cells per knee, respectively) to assess differences in treatment effects and to assess the systemic safety of MSC therapy. Evaluate the effectiveness of cell transplantation through ultrasound, MRI, pathology. Evaluate the safety of cell transplantation through hematological tests and CT scans. Finally, collect the joint cartilage and synovium of the higher dose transplant group, model group, and normal group of cynomolgus macaque, and analyze the treatment mechanism through 10X single-cell sequencing.
|
|
|
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Dec 19, 2023 |
Last update date |
May 01, 2024 |
Contact name |
Yan Yaping |
E-mail(s) |
[email protected]
|
Organization name |
Macaca fascicularis
|
Department |
Yunnan Key Laboratory of Primate Biomedical Research & Institute of Primate Translational Medicine
|
Street address |
727 South Jingming Road, Chenggong District
|
City |
Kunming |
State/province |
Yunnan |
ZIP/Postal code |
650500 |
Country |
China |
|
|
Platforms (1) |
GPL28212 |
Illumina NovaSeq 6000 (Macaca fascicularis) |
|
Samples (30)
|
GSM7981752 |
cartilage, msc_treat rep4 |
GSM7981753 |
cartilage, OA_model rep1 |
GSM7981754 |
cartilage, OA_model rep2 |
GSM7981755 |
cartilage, OA_model rep3 |
GSM7981756 |
cartilage, normal rep1 |
GSM7981757 |
cartilage, normal rep2 |
GSM7981758 |
cartilage, normal rep3 |
GSM7981759 |
cartilage, normal rep4 |
GSM7981760 |
cartilage, normal rep5 |
GSM7981761 |
cartilage, normal rep6 |
GSM7981762 |
cartilage, normal rep7 |
GSM7981763 |
synovium, msc_treat rep1 |
GSM7981764 |
synovium, msc_treat rep2 |
GSM7981765 |
synovium, msc_treat rep3 |
GSM7981766 |
synovium, msc_treat rep4 |
GSM7981767 |
synovium, msc_treat rep5 |
GSM7981768 |
synovium, msc_treat rep6 |
GSM7981769 |
synovium, OA_model rep1 |
GSM7981770 |
synovium, OA_model rep2 |
GSM7981771 |
synovium, OA_model rep3 |
GSM7981772 |
synovium, normal rep1 |
GSM7981773 |
synovium, normal rep2 |
GSM7981774 |
synovium, normal rep3 |
GSM7981775 |
synovium, normal rep4 |
GSM7981776 |
synovium, normal rep5 |
GSM7981777 |
synovium, normal rep6 |
GSM7981778 |
synovium, normal rep7 |
|
Relations |
BioProject |
PRJNA1054550 |
Supplementary file |
Size |
Download |
File type/resource |
GSE250569_cartilage_processed.tar.gz |
449.2 Mb |
(ftp)(http) |
TAR |
GSE250569_synovium_processed.tar.gz |
571.2 Mb |
(ftp)(http) |
TAR |
SRA Run Selector |
Raw data are available in SRA |
|
|
|
|
|